-
Adverum Biotechnologies Inc. NASDAQ:ADVM Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.
Location: 800 Saginaw Drive, California, 94063, US | Website: adverum.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
77.29M
Cash
153.2M
Avg Qtr Burn
-21.39M
Short % of Float
12.75%
Insider Ownership
11.67%
Institutional Own.
94.02%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept) Details Wet age-related macular degeneration , Age-related macular degeneration, Eye disease | Phase 2 Data readout | |
ADVM-022 (AAV.7m8 Afiblercept) Details Diabetes, Eye disease , Diabetic macular edema | Failed Discontinued |